SCHEMBL1709031

SCHEMBL1709031

CC1C(=O)C[C@@H](O)C1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14629087 1.00
SCHEMBL12450248 1.00
SCHEMBL1709034 1.00
SCHEMBL14226930 1.00
SCHEMBL12928668 1.00
SCHEMBL14629088 1.00
SCHEMBL12225583 1.00
SCHEMBL12928471 1.00
SCHEMBL27277795 0.77 CYP2D6 (0.34)
SCHEMBL24483924 0.75 CA1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2627647-B1 PROCESSES FOR PREPARATION OF LUBIPROSTONE SCINOPHARM (KUNSHAN) BIOCHEMICAL TECH CO LTD (CN) 2016-12-14 EP disclosed
US-8962688-B2 Method for the treatment of gastrointestinal disorders SUCAMPO AG (CH) 2015-02-24 US disclosed
US-8962688-B2 Method for the treatment of gastrointestinal disorders SUCAMPO AG (CH) 2015-02-24 US disclosed
US-20140315994-A1 METHOD FOR TREATING GASTROINTESTINAL DISORDER SUCAMPO AG (CH) 2014-10-23 US disclosed
US-20140315994-A1 METHOD FOR TREATING GASTROINTESTINAL DISORDER SUCAMPO AG (CH) 2014-10-23 US disclosed
US-8846958-B2 Process for the preparation of lubiprostone SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD. (CN) 2014-09-30 US disclosed
US-8846958-B2 Process for the preparation of lubiprostone SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD. (CN) 2014-09-30 US disclosed
US-20140235665-A1 ANTI-CONSTIPATION COMPOSITION SUCAMPO AG (CH) 2014-08-21 US disclosed
US-20140235665-A1 ANTI-CONSTIPATION COMPOSITION SUCAMPO AG (CH) 2014-08-21 US disclosed
US-8748481-B2 Method for treating gastrointestinal disorder SUCAMPO AG (CH) 2014-06-10 US disclosed
US-20090030072-A1 PHARMACEUTICAL COMBINATION OF OPIOID AND PROSTAGLANDIN COMPOUND SUCAMPO AG (CH) 2009-01-29 US disclosed
US-20090030072-A1 PHARMACEUTICAL COMBINATION OF OPIOID AND PROSTAGLANDIN COMPOUND SUCAMPO AG (CH) 2009-01-29 US disclosed
US-20090012165-A1 PHARMACEUTICAL COMBINATION OF NSAID AND PROSTAGLANDIN COMPOUND SUCAMPO AG (CH) 2009-01-08 US disclosed
US-20090012165-A1 PHARMACEUTICAL COMBINATION OF NSAID AND PROSTAGLANDIN COMPOUND SUCAMPO AG (CH) 2009-01-08 US disclosed
US-7355064-B2 Method for preparing 15-keto-prostaglandin E derivative R-TECH UENO, LTD. (JP) 2008-04-08 US disclosed
US-7355064-B2 Method for preparing 15-keto-prostaglandin E derivative R-TECH UENO, LTD. (JP) 2008-04-08 US disclosed
US-20070276006-A1 Method for the treatment of gastrointestinal disorders SUCAMPO AG 2007-11-29 US disclosed
US-20070276006-A1 Method for the treatment of gastrointestinal disorders SUCAMPO AG 2007-11-29 US disclosed
US-20070185206-A1 Method for preparing 15-keto-prostaglandin E derivative R-TECH UENO, LTD. (JP) 2007-08-09 US disclosed
US-20070185206-A1 Method for preparing 15-keto-prostaglandin E derivative R-TECH UENO, LTD. (JP) 2007-08-09 US disclosed